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290 The Journal of Thoracic and CardioObjective: The activation of the coagulation and fibrinolytic systems and platelet
function in patients undergoing coronary artery bypass surgery on-pump or off-
pump techniques was compared.
Methods: Thirty-two patients were randomly assigned to on-pump or off-pump
coronary artery bypass grafting. Heparin was given at the same dose. Activation of
the coagulation and fibrinolytic systems was evaluated by measurement of several
markers. Platelet function was evaluated by in vitro bleeding time test. Blood
samples were collected at 7 different times, up to postoperative day 6.
Results: Overall tissue factor production was similar in the two groups. Thrombin
formation was more elevated in the on-pump group (P  .001), particularly during
the operation; prothrombin fragment 1.2 discharge values were higher than the
preoperative ones (P  .002). Levels of tissue-plasminogen activator showed no
difference between the groups (P .1). D-dimers release was higher in the on-pump
group (P  .0002). In vitro bleeding time was longer in the on-pump group
(P  .0001), particularly in the first 24 hours; it was not prolonged in the off-pump
group. In both groups, regardless of aspirin treatment, discharge in vitro bleeding
times were lower than the preoperative ones (P  .01).
Conclusion: Although the extrinsic coagulation pathway is similarly activated,
thrombin formation is more pronounced in patients having on-pump bypass graft-
ing. Patients subjected to off-pump bypass grafting have normally functioning
platelets and a weak activation of the fibrinolytic system. At discharge, both groups
have preserved platelet function and increased thrombin formation. Further studies
with angiographic evaluation are needed to establish a correlation between coagu-
lation parameters, platelet function, and graft patency.
Off-pump coronary artery bypass grafting (OPCAB) is frequently used toperform coronary artery bypass grafting (CABG). The advantages anddisadvantages of this technique in comparison with the standard operation
performed with the arrested heart and cardiopulmonary bypass (CPB) are becoming
clearer. Most of the studies involving the general population1,2 have shown that a
significant reduction of postoperative bleeding and blood product transfusion is
observed after OPCAB compared with on-pump operations. Moreover, subgroup
analysis of patients with a higher rate of comorbidities (older age, renal failure,
diabetes, previous stroke, calcific aorta) showed that the OPCAB technique might
reduce operative mortality and morbidity.3,4
Coagulation disorders and consequent perioperative bleeding represent one of the
most frequent complications of on-pump surgery. Excessive bleeding, blood product
transfusion, and chest reopening for bleeding are widely known risk factors for
vascular Surgery ● February 2006
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Padverse events after on-pump surgery.5 Consequently, sev-
eral strategies (technical, pharmacologic) aimed to reduce
the risk of excessive bleeding have been adopted during
on-pump surgery. Such strategies have also been suggested
for patients undergoing OPCAB,6 although this technique,
due to the absence of CPB, may result in a different coag-
ulative state.
So far few studies have analyzed the coagulation and
fibrinolytic systems during and after OPCAB in comparison
with on-pump operations.7-9 A recent editorial10 hypothe-
sized that OPCAB patients may have a higher risk of early
graft failure because of the reduced activation of the fibrino-
lytic system associated with an enhanced activation of the
inflammatory and coagulation systems.
The aim of the present study is to evaluate the difference
in the activation of coagulation and fibrinolytic systems and
platelet function in patients undergoing OPCAB operations
or standard on-pump CABG.
Methods
The local ethics committee approved the study protocol. After
informed consent, 32 consecutive patients requiring elective
CABG, considered suitable for both on-pump and OPCAB proce-
dures, were enrolled in the study. The patients were assigned in a
randomized fashion to the on-pump group or the OPCAB group.
The following exclusion criteria have been applied:
Preoperative: Known pre-existing hemolytic or coagulative disor-
ders; oral or intravenous anticoagulant treatment; all kinds of
antiplatelet treatment taken within 5 days before the operation.
Intraoperative: Intolerance from a hemodynamic point of view to
the lifting of the heart and the exposure necessary to perform
OPCAB; patients with coronary arteries surgically inaccessible
(intramyocardial) for a beating heart operation; patients in
whom a complete revascularization was not achievable with
OPCAB (in these cases, patients have been converted to receive
on-pump CABG and have been excluded from the study).
Perioperative Management
After premedication with lorazepam, anaesthesia was induced with
a combination of fentanyl, midazolam, and sodium thiopenthal and
Abbreviations and Acronyms
ANOVA analysis of variance
CABG  coronary artery bypass grafting
CPB  cardiopulmonary bypass
ELISA  enzyme-linked immunosorbent assay
OPCAB off-pump CABG
PAI-1  plasminogen activator inhibitor-1
PF  prothrombin fragment
POD  postoperative day
TF  tissue factormaintained with proprofol. Antifibrinolytic drugs were not admin-
The Journal of Thoraciistered. Heparin was given at the same dose (300 U/kg) in both
groups. Intraoperative heparin monitoring was performed by stan-
dard activated clotting time (Hemochron 8; ITC, a subsidiary of
Thoratec Corporation, Pleasanton, Calif). Additional heparin bolus
(5000 U) was given if the activated clotting time was below 400
seconds in the on-pump group and below 300 seconds in the
OPCAB group. In both groups protamine was administered to
reverse heparin (1 mg of protamine/100 IU of heparin). In the
on-pump group CPB was established with a 2-stage venous can-
nula and aortic return. Moderate hypothermia (34°C) was main-
tained during the operation. Cardiac arrest was induced and main-
tained with antegrade cold blood cardioplegia. Cardiotomy suction
was used in all patients of the on-pump group. Cell saving devices
were not used. A heart stabilizer (Octopus; Medtronic Inc, Min-
neapolis, Minn) has been used in all OPCAB operations and
intracoronary shunts have been used in 87% of these cases to allow
bloodless anastomoses.
All patients were admitted postoperatively in the intensive care
unit and extubated when hemodynamically stable, fully rewarmed,
awake, without surgical bleeding, and with optimal blood gases.
Postoperatively, patients received aspirin (100 mg orally or intra-
venously) and low molecular weight heparin (nadroparin 2850 U
Anti-Xa, subcutaneously) starting 12 hours after the end of the
operation in the absence of significant mediastinal bleeding. Low
molecular weight heparin administration was discontinued on
postoperative day 5.
Assays
Specific assays were performed to assess the activation of coagu-
lation and fibrinolytic systems between the two groups. Blood
samples were centrifuged for 15 minutes at 3500 rpm and frozen
at 80°C until assayed. Plasma was assayed by monoclonal anti-
bodies sandwich enzyme-linked immunosorbent assay (ELISA)
technique.
Activation of the coagulation system was evaluated by use of
the prothrombin fragment 1.2 (PF-1.2) (Enzygnost F12 Micro;
Dade Behring Marburg GmbH, Marburg, Germany), tissue factor
(TF) (IMUBIND Tissue Factor ELISA; American Diagnostica
GmbH, Pfungstadt, Germany), and fibrinogen (Biopool Fibrinogen
Assay Kit, Biopool International, Ventura, Calif) measurements.
Activation of the fibrinolytic system was evaluated by measuring
tissue plasminogen activator (IMUBIND tPA ELISA; American
Diagnostica GmbH, Pfungstadt, Germany), plasminogen activator
inhibitor-1 (PAI-1) ( IMUBIND Plasma PAI-1 ELISA; American
Diagnostica GmbH, Pfungstadt, Germany), and D-dimers (ACL
9000, IL Instrumentation Laboratory, Arcore (MI), Italy).
Platelet function was evaluated by the platelet function ana-
lyzer (PFA-100; Sysmex UK Ltd, Milton Keynes, United King-
dom), a device designed to simulate platelet-dependent hemostasis
in whole blood in vitro.11 The system consists of a cartridge in
which a membrane and an aperture are coated with collagen/
adenosine-5=-diphosphate. Anticoagulated whole blood is aspi-
rated through a capillary under steady high shear rates. The pres-
ence of the platelet agonist and the high shear rates result in a
platelet plug that gradually occludes the aperture. The time re-
quired for full occlusion of the aperture is defined closure time
(range: 71-118 seconds). PFA-100 measuring was done 15 minutes
after blood sampling.
c and Cardiovascular Surgery ● Volume 131, Number 2 291
cked
Cardiopulmonary Support and Physiology Paparella et al
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sured at all sample times.
All ELISA assays were doubled tested, and the mean value was
used for analysis. Results were corrected for hemodilution accord-
ing to the formula: (corrected assay)Tx  (assay)Tx 
(HKT)T0/(HKT)Tx.
Sample Times
Blood samples were collected at 7 different times, before, during
and after the operation: T0: during induction before the beginning
of the operation; T1: 45 minutes after heparin administration; T2:
15 minutes after protamine administration; T3: 3 hours after the
end of the operation; T4: first postoperative day (POD); T5: fourth
POD; T6: sixth POD. Samples for firbrinogen were not performed
at T1 and T2.
Statistical Analysis
On the basis of preliminary data obtained with PFA-100, the trial
was designed to enroll 30 patients to demonstrate a 50% reduction
of in vitro bleeding time and coagulation markers after the oper-
ation in the OPCAB group compared with the on-pump group
(alpha  .05, power  0.8). Results of the measured coagulation
parameters showed a nonnormal distribution. Logarithmic conver-
sion of data was carried out to apply repeated-measures analysis of
variance (ANOVA) for overall comparison between the groups
and the Student t test to compare measured outcomes at each
sample time. The Wilcoxon test was applied to compare preoper-
ative values (T0) with postoperative values (T6) within each
group. Categorical variables are presented as absolute numbers and
percentages were compared using the Fisher exact test. Statistical
analyses were performed using the Stat-View Statistical Software
Package (SAS Institute Inc, Cary, NC) and Number Cruncher
TABLE 1. Intraoperative characteristics and postoperative
On-pump group
Operation time (min) 303.8
Heparinization time (min) 159.6
Heparin dose 4.6
CPB (min) 107
Aortic crossclamping (min) 64.9
CABG (No.) 3.25
IABP use 0
ICU stay (d) 1.62
ARF (creatinine 2.5 mg/dL) 1 (6.2
AF 2 (12.
Total blood loss (mL) 861.2
Mediastinal blood loss (mL) 508.1
Pleuritic blood loss (mL) 353.1
Total blood product transfusion (units) 2.1
PRC transfusion (unit) 2.1
Hgb, g/dL value at POD 6 9.3
Mortality rate 1 (6.2
OPCAB, Off-pump coronary artery bypass; CPB, cardiopulmonary bypass;
intensive care unit; ARF, acute renal failure; AF, atrial fibrillation; PRC, paStatistical System (NCSS, Kaysville, Utah).
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One patient of the OPCAB group did not tolerate the lifting
of the heart; he was converted to on-pump treatment and
consequently was excluded from the study.
Preoperative patient characteristics were similar in the
two study groups: age, gender, ejection fraction, cardiovas-
cular risk factors, and body mass index were equally rep-
resented in the groups. The operation length and the number
of grafts performed (3.25 vs 2.7) were slightly greater in the
on-pump group without a statistically significant difference.
However, duration of heparinization was significantly
longer in the on-pump group (Table 1). No differences in
clinical outcomes were observed between on-pump and
OPCAB patients (Table 1). Postoperative blood loss and
blood product transfusion were also comparable, but hemo-
globin values measured on POD 6 were higher in the
OPCAB group.
TF serum levels (Figure 1, A) were comparable between
the two groups (2-way ANOVA for repeated measures:
P  .11 corrected for hemodilution; P .54 not corrected
for hemodilution). TF levels measured before discharge
were above the levels measured preoperatively (P .001 in
both groups). Serum levels of PF-1.2 (Figure 1, B) were
significantly higher in the on-pump group particularly dur-
ing and immediately after CPB (2-way ANOVA for re-
peated measures: P  .0001 corrected and not corrected for
hemodilution; Table 2). In both groups, PF-1.2 tends to rise
in the postoperative period: PF-1.2 levels measured at T6
were significantly higher than those measured at T0 (P 
ome
atients) OPCAB group (15 patients) P value
289 38.8 NS
121.6 35.7 .009
4.0  0.5 .009
2.7  0.8 NS
0
1.53  1.06 NS
0 NS
4 (26.6%) NS
3 933.7 382.6 NS
1 539 221.2 NS
3 394.6 239.5 NS
1.3  1.2 NS
1.3  1.2 NS
10.9 1.35 .02
0 NS
G, coronary artery bypass grafting; IABP, intra-aortic balloon pump; ICU,
red cells; Hgb, hemoglobin; POD, postoperative day; NS, not significant.outc
(16 p
88.1
40.4
0.6
21.2
19.3
0.86
1.5
5%)
5%)
340.
246.
201.
2.7
2.7
2.34
5%)
CAB.002 in both groups). Fibrinogen levels (Table 2) did not
uary 2006
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Pdiffer between the groups (P .5). Discharge values of
fibrinogen were higher than preoperatively (P  .001 and
.006 for on-pump and OPCAB groups, respectively). Levels
of T-PA (Figure 2, A) showed no difference between the
Figure 1. A, Tissue factor (TF) values after log transforma
Prothrombin fragments 1.2 (PF 1.2) values after log transforma
squares, On-pump group; filled circles, OPCAB group. Signi
TABLE 2. Coagulation and fibrinolytic markers after corr
different sample times with P values
T0 T1 T2
TF (pg/mL)
On 91.92 11.58 112.36 34.84 141.31 7.2
Off 105.24 23.7 101.05 29.78 113.01 29.
P .66 .28 .04
PF-1.2 (nmol/L)
On 2.43 0.61 3.17 0.72 8.09 1.6
Off 2.06 0.47 2.4 0.13 2.46 0.6
P .49 .021 .00001
TPA (ng/mL)
On 18.36 24.2 40.65 49.44 26.62 19.
Off 10.73 9.39 11.76 7.16 17.02 8.7
P 0.94 .26 .21
PAI (ng/mL)
On 18.06 10.68 26.78 11.68 69.48 29.
Off 21.15 8.15 31.47 2.86 37.41 4.9
P .85 .81 .002
D-dimer (ng/mL)
On 193.71 79.9 531.94 1292.38 1692.95 144
Off 249.2 4.95 268.25 110.42 250.07 50.
P .87 .42 .01
PFA-100 (s)
On 89.33 27.14 189.09 82.65 154.7 77.
Off 91.2 15.64 93.92 37.88 78.85 14.
P .61 .003 .0003
Fibrinogen (mg/dL)
On 424  105.2
Off 439.8 135.3
P .84TF, Tissue factor; PF, prothrombin fragment; TPA, tissue plasminogen factor; PA
The Journal of Thoracigroups (2-way ANOVA for repeated measures: P  .07
corrected for hemodilution; P .36 not corrected for he-
modilution). At discharge in both groups, tissue plasmino-
gen activator levels were comparable with those obtained
nd correction for hemodilution in 7 observation times. B,
nd correction for hemodilution in 7 observation times.Open
P values obtained with the t test are reported.
n for hemodilution and platelet function measured at 7
T3 T4 T5 T6
115.93 39.61 121.83 97.32 175.82 100.11 149.32 55.76
96.07 23.42 106.18 57.72 147.57 70.53 143.12 43.81
.09 .23 .06 .42
5.51 0.8 2.83 0.05 4.37 0.72 4.75 0.84
3.35 1.25 2.7 1.58 4.08 0.86 4.19 1.45
.008 .92 .26 .22
25.17 10.26 16.45 8.63 17.86 10.25 14.93 7.9
19.79 12.28 15.75 9.87 12.54 8.75 14.79 8.85
.60 .66 .85 .77
93.03 76.7 63.28 77.99 40.28 2.37 33.47 18.16
75.41 13.82 59.51 87.38 35.7 14.18 34.32 11.43
.24 .83 .71 .94
199.86 499.35 536.81 357.31 422.84 324.71 609.18 328.61
386.72 493.7 400.45 283.4 441.83 257.13 777.76 512.88
.08 .49 .82 .91
119.2 79.38 75.14 22.38 70.85 10.17 63.15 8.86
68 18.17 92.79 19.77 62.69 14.56 61.07 6.87
.01 .23 .08 .53
380.2 109.8 568 182.9 752.1 164.4 695.4 155.3
421.9 134.2 521 196.3 688.4 149.8 667.1 162.2
.43 .44 .28 .61tion a
tion a
ficantectio
8
3
6
3
84
9
45
7
5.1 1
09
31
65I, plasminogen activator inhibitor; PFA-100, platelet function analyzer-100.
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CSPpreoperatively. Perioperative PAI-1 levels (Figure 2, B)
were higher in the on-pump group (2-way ANOVA for
repeated measures: P  .03 corrected and not corrected for
hemodilution); they rose consistently also in the OPCAB
group 3 hours and 24 hours after the end of the operation. At
discharge, PAI-1 levels were significantly higher than pre-
operatively (P .001 and .002 in the on-pump and OPCAB
groups, respectively). There was an increase of D-dimers
soon after the beginning of the operation in both groups
(Figure 3, A), but the overall release of D-dimers was
significantly more pronounced in the on-pump group (2-
way ANOVA for repeated measures: P .0001 corrected
and not corrected for hemodilution). D-dimers levels re-
mained elevated throughout the study period; at T6 they
were significantly higher than at T0 (P  .01 and .02 in the
on-pump and OPCAB groups, respectively).
PFA-100 analysis demonstrated significantly longer clo-
sure times for the on-pump patients (P  .0001), particu-
Figure 2. A, Tissue plasminogen activator (TPA) values
7 observation times. B, Plasminogen activator inhibitor
hemodilution in 7 observation times. Open squares, O
values obtained with the t test are reported.
Figure 3. A, D-dimer (D-D) values after log transformat
B, Platelet function evaluated by the platelet funct
observation times. Two-way ANOVA for repeated meas
OPCAB group. Significant P values obtained with the294 The Journal of Thoracic and Cardiovascular Surgery ● Febrlarly at T1, T2, and T3 (Figure 3, B). PFA-100 closure time
was not prolonged at all in the OPCAB group during hep-
arinization. Regardless of aspirin treatment, discharge val-
ues (T6) of PFA-100 were lower than the preoperative ones
(P  .007 and .001 in the on-pump and OPCAB groups,
respectively).
Discussion
CABG performed with CPB is a safe operation that
achieves excellent short- and long-term results. Currently,
CPB is associated with a number of adverse effects that may
have a negative impact on an aging CABG population.
Consequently, OPCAB has been developed to avoid the use
of CPB and maintain a more physiologic coagulation and
inflammatory state. Previous studies have shown that this
hypothesis is only partially true. Gu and colleagues12 dem-
onstrated that the inflammatory response is reduced but not
abolished in patients undergoing OPCAB operations. The
r log transformation and correction for hemodilution in
I-1) values after log transformation and correction for
mp group; filled circles, OPCAB group. Significant P
nd correction for hemodilution in 7 observation times.
nalyser-100 (PFA-100) after log transformation in 7
P<.0001. Open squares, On-pump group; filled circles,
are reported.afte
-1 (PA
n-puion a
ion a
ures:uary 2006
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Psame group prospectively studied 22 patients with single-
vessel disease who underwent OPCAB either through a
median sternotomy or with minimally invasive thoracot-
omy: markers of activated coagulation system were detected
24 hours after the operation.7
Other studies have consequently compared the activation
of the coagulation system in patients undergoing CABG
with or without CPB. Englberger and colleagues8 analyzed
27 patients assigned in a randomized fashion to undergo
myocardial revascularization either with the off-pump tech-
nique (9 patients) or with CPB (16 patients). Plasma levels
of fibrin monomer, thrombin-antithrombin complex, and
D-dimer were significantly higher in the on-pump group
immediately after surgery, whereas they were similar 18
hours postoperatively. Their study is limited by the short
period of observation: 18 hours after the end of the opera-
tion. Lo and colleagues9 evaluated 40 patients undergoing
coronary surgery with or without CPB. Blood samples were
drawn up to 96 hours after the end of the operation. PF-1.2
and D-dimer levels were significantly higher in the on-pump
group at the end of the operation and 2 hours later; in
OPCAB patients, PF-1.2 levels significantly increased 2
hours after the operation and peaked on POD day 4. In both
groups, plasma concentrations of von Willebrand factor
increased from the first POD compared with baseline and
peaked at POD 4.
Our study adds some new insights to the results of the
previously published reports.
The role of the extrinsic coagulation pathway and TF in
the post-CPB coagulation state has been well documented.13
We compared, for the first time, TF production with and
without CPB. We found no significant difference in TF
production between on-pump and OPCAB patients, mean-
ing that surgical trauma, even in the absence of CPB and
cardiotomy suction, leads to the activation of the extrinsic
pathway. In both groups, TF levels rise in the postoperative
phase, probably as a result of a systemic inflammatory state
rather than as a response to a topical prothrombotic stimu-
lus. This is confirmed by the similar perioperative trend of
fibrinogen, a widely known inflammatory marker. Fibrino-
gen is the substrate for the fibrin production, participates in
platelet aggregation, and acts as acute phase protein, in-
creasing during the inflammatory responses.14 The inflam-
matory and coagulation systems share a common activation
pathway. The link is represented by nuclear factor B.
Nuclear factor B, during CPB, regulates TF activation and
consequent thrombin release. Nuclear factor B regulates
also the inflammatory response secondary to CPB surgery.15
Our study confirms that during CPB, despite heparin
administration, thrombin formation is not prevented.16 Con-
sidering the relevant perioperative difference of thrombin
formation associated with similar TF values between the
groups, our study suggests that the extrinsic pathway and TF
The Journal of Thoracishould not be considered the only trigger for thrombin
formation during CPB and that the intrinsic pathway also
plays a role. In contrast, in OPCAB patients, administration
of a heparin dose similar to the one used during CPB (300
U/Kg) eliminates the production of thrombin during the
time of surgery. Future trials will clarify the optimal heparin
management in patients undergoing OPCAB. We also dem-
onstrated that in OPCAB patients there is an increase of
PF-1.2 production (corresponding to TF increase) starting
on POD 2 and continuing to at least POD 7. Levels are
comparable with those observed in patients undergoing
on-pump CABG. Patients of both groups received low mo-
lecular weight heparin postoperatively; measured procoagu-
lant markers levels may have been affected by such treat-
ment as it has been demonstrated in other clinical settings.17
Nevertheless, we believe that administration of low molec-
ular weight heparin could not alter the comparison between
the groups.
The correlation between plasma activation of procoagu-
lation markers and clinical outcome (namely graft patency)
is still a matter of debate. Moor and colleagues18 found that
the percentage increase in PAI-1 activity on the first post-
operative day was significantly higher in patients who sub-
sequently were found to have vein graft occlusion at angio-
graphic evaluation 3 months after CABG. In our study,
PAI-1 levels were more elevated in the on-pump patients,
although a steady increase was observed also in the OPCAB
group. In both groups, peak release was observed 3 hours
after the end of the operation. At the same time, tPA release
was very modestly stimulated, particularly in the OPCAB
patients. We also observed that fibrinolysis (D-dimer) is
activated to a lesser extent in OPCAB patients. On the basis
of our observation, the proposed use of antifibrinolytic
agents in OPCAB patients6 seems unjustified unless future
randomized trials with angiographic control studies will
prove the safety of antifibrinolytic administration with re-
gard to graft patency.
Platelet function, as analyzed by an in vitro bleeding test,
is better preserved during OPCAB surgery than during
CPB. The lack of CPB and cardiotomy suction, together
with the reduced formation of thrombin, may explain why
platelet function is preserved in OPCAB patients. The pre-
served platelet function did not affect blood loss or trans-
fusion rates in our study. These findings are in contrast to
other studies that have shown a reduction of both blood loss
and transfusion in off-pump patients, although our sample
size is not sufficiently large to produce reliable clinical
outcome data. The administration of aspirin 100 mg daily
from POD 1 does not affect platelet function postopera-
tively. In both groups, bleeding times measured at discharge
were lower than those measured preoperatively. PFA-100
has already been used to assess platelet dysfunction in
patients undergoing CPB surgery19; it is a validated method
c and Cardiovascular Surgery ● Volume 131, Number 2 295
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disease20 and to measure aspirin resistance in patients with
coronary artery disease, showing that 35% of patients who
had had acute myocardial infarction seemed to be nonre-
sponders to long-term aspirin therapy in doses of 75 and 160
mg/day.21 Other studies have evaluated platelet function in
OPCAB patients22,23; nevertheless, our study provides the
longest observation suggesting that dosages of aspirin 100
mg daily may be insufficient to prevent vein graft failure.
We hypothesize that the activated inflammatory and coag-
ulative state observed after cardiac operations, by increasing
von Willebrand factor release9 and platelet leukocytes ag-
gregates, may influence platelet response to aspirin treat-
ment; future studies should clarify whether treatment aimed
to attenuate these systems may also decrease aspirin
resistance.
Vein graft failure remains a major problem after CABG.
Occlusion in the first weeks is secondary to thrombosis,
whereas intimal hyperplasia and eventually atherosclerotic
changes with superimposed thrombus formation underlie
subsequent closure. Two recent randomized controlled
trials24,25 revealed that patency rate was significantly worse
in patients undergone off-pump procedures compared with
patients undergoing CPB. Moreover, data from a large
registry demonstrate that off-pump patients have a higher
rate of perioperative myocardial infarction and have a sig-
nificantly worse 3-year risk-adjusted survival.26 There are
several possible explanations for the poorer graft perfor-
mance in patients operated on by the off-pump technique:
the poorer coronary vessel exposure, heart movement, poor
coronary visualization provoked by bleeding, all render the
distal anastomosis more difficult to perform and sometimes
less accurate than those made with the heart arrested. The
tools used during the anastomoses (intracoronary shunts,
coronary occluding stitch, carbon dioxide blower) to im-
prove visualization may all potentially damage the coronary
and graft endothelium.27 Our study shows that the coagu-
lation state of OPCAB patients differs from that of the
on-pump group only during the first 24 hours. Of particular
interest is the lack of platelet dysfunction observed during
this period in the OPCAB patients associated with the lack
of fibrinolysis. It remains to be demonstrated whether this
association should be considered a procoagulative state.
After the first 24 hours, both groups continue to produce
thrombin probably as a consequence of their inflammatory
state rather than the intraoperative procoagulative stimulus.
This is associated with an increased platelet function, as
measured by a platelet function analyzer (PFA-100). The
actual antiplatelet treatment is not adequate to protect the
graft from early thrombosis. Our data would support the
addition of more aggressive antiplatelet and antithrombotic
drug regimens in both on- and off-pump patients to decrease
vein graft failure. We believe this might be particularly
296 The Journal of Thoracic and Cardiovascular Surgery ● Febrhelpful in OPCAB patients in whom less accurate distal
anastomosis and coronary artery endothelial damage may
occur. Further studies with angiographic evaluation are
needed to establish a correlation between coagulation pa-
rameters, antiplatelet treatment, and graft patency.
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